Diazadispiroalkane Derivatives Are New Viral Entry Inhibitors.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
18 03 2021
Historique:
received: 02 10 2020
accepted: 18 01 2021
pubmed: 27 1 2021
medline: 22 6 2021
entrez: 26 1 2021
Statut: epublish

Résumé

Herpesviruses are widespread and can cause serious illness. Many currently available antiviral drugs have limited effects, result in rapid development of resistance, and often exhibit dose-dependent toxicity. Especially for human cytomegalovirus (HCMV), new well-tolerated compounds with novel mechanisms of action are urgently needed. In this study, we characterized the antiviral activity of two new diazadispiroalkane derivatives, 11826091 and 11826236. These two small molecules exhibited strong activity against low-passage-number HCMV. Pretreatment of cell-free virus with these compounds greatly reduced infection. Time-of-addition assays where 11826091 or 11826236 was added to cells before infection, before and during infection, or during or after infection demonstrated an inhibitory effect on early steps of infection. Interestingly, 11826236 had an effect by addition to cells after infection. Results from entry assays showed the major effect to be on attachment. Only 11826236 had a minimal effect on penetration comparable to heparin. Further, no effect on virus infection was found for cell lines with a defect in heparan sulfate expression or lacking all surface glycosaminoglycans, indicating that these small molecules bind to heparan sulfate on the cell surface. To test this further, we extended our analyses to pseudorabies virus (PrV), a member of the

Identifiants

pubmed: 33495228
pii: AAC.02103-20
doi: 10.1128/AAC.02103-20
pmc: PMC8097465
pii:
doi:

Substances chimiques

Alkanes 0
Antiviral Agents 0
Glycosaminoglycans 0
Spiro Compounds 0
Viral Envelope Proteins 0
Heparin 9005-49-6
Heparitin Sulfate 9050-30-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 American Society for Microbiology.

Références

J Virol. 2003 Dec;77(24):12961-7
pubmed: 14645552
Antiviral Res. 2002 Jul;55(1):117-27
pubmed: 12076756
Cell Microbiol. 2004 May;6(5):401-10
pubmed: 15056211
Curr Opin Organ Transplant. 2018 Aug;23(4):388-394
pubmed: 29794552
J Virol. 2020 Aug 31;94(18):
pubmed: 32641474
J Gen Virol. 2002 Feb;83(Pt 2):291-300
pubmed: 11807221
Transpl Infect Dis. 1999 Jun;1(2):105-14
pubmed: 11428978
Antiviral Res. 2017 Jan;137:102-107
pubmed: 27871886
Antimicrob Agents Chemother. 2014;58(4):1963-71
pubmed: 24419339
J Virol. 1993 Jan;67(1):93-100
pubmed: 8380101
BMC Infect Dis. 2017 Jul 17;17(1):501
pubmed: 28716027
Antimicrob Agents Chemother. 2005 Mar;49(3):873-83
pubmed: 15728878
Acta Gastroenterol Belg. 2012 Sep;75(3):316-21
pubmed: 23082701
J Gen Virol. 2002 Feb;83(Pt 2):301-309
pubmed: 11807222
J Biol Chem. 2006 Dec 15;281(50):38668-74
pubmed: 17040900
J Virol. 2007 Oct;81(20):10970-80
pubmed: 17686860
J Virol. 2012 Jun;86(12):6434-43
pubmed: 22491462
Virology. 2002 Aug 1;299(2):279-287
pubmed: 12202231
Virology. 2010 Feb 20;397(2):389-98
pubmed: 20004926
Virology. 1993 Apr;193(2):834-41
pubmed: 8384757
Virology. 1959 Apr;7(4):394-407
pubmed: 13669311
J Virol. 2000 Nov;74(22):10508-13
pubmed: 11044095
J Virol. 1992 Mar;66(3):1761-4
pubmed: 1310777
Virology. 1993 Jan;192(1):361-4
pubmed: 7685967
Antiviral Res. 2006 Sep;71(2-3):154-63
pubmed: 16765457
J Antimicrob Chemother. 2007 Jul;60(1):68-77
pubmed: 17550890
Antimicrob Agents Chemother. 1987 Apr;31(4):544-50
pubmed: 3037998
J Virol. 2009 Apr;83(8):3891-903
pubmed: 19193805
Expert Rev Anti Infect Ther. 2013 Jun;11(6):547-9
pubmed: 23750725
J Med Virol. 2013 May;85(5):893-8
pubmed: 23508914
Eksp Klin Farmakol. 2004 May-Jun;67(3):30-3
pubmed: 15341064
J Virol. 1995 Jun;69(6):3290-8
pubmed: 7745676
J Virol. 2005 Mar;79(5):2754-67
pubmed: 15708994
Virology. 1993 Jun;194(2):654-64
pubmed: 8389078
J Virol. 1988 Jan;62(1):12-9
pubmed: 2824839
N Engl J Med. 1996 Sep 5;335(10):721-9
pubmed: 8786764
Antimicrob Agents Chemother. 2012 Oct;56(10):5278-88
pubmed: 22850525

Auteurs

Rebekka Adfeldt (R)

Charité-Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany.

Janna Schmitz (J)

Charité-Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany.

Barbara Kropff (B)

Universitätsklinikum Erlangen, Institute of Clinical and Molecular Virology, Erlangen, Germany.

Marco Thomas (M)

Universitätsklinikum Erlangen, Institute of Clinical and Molecular Virology, Erlangen, Germany.

Natalia Monakhova (N)

FRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow, Russia.

Julia E Hölper (JE)

Federal Research Institute for Animal Health, Friedrich-Loeffler-Institut, Griefswald, Germany.

Barbara G Klupp (BG)

Federal Research Institute for Animal Health, Friedrich-Loeffler-Institut, Griefswald, Germany.

Thomas C Mettenleiter (TC)

Federal Research Institute for Animal Health, Friedrich-Loeffler-Institut, Griefswald, Germany.

Vadim Makarov (V)

FRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow, Russia.

Elke Bogner (E)

Charité-Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany elke.bogner@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH